Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1ZHML)

Drug Name

HPN328 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Delta-like protein 3 (DLL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rova-T	DMNGCAD	Small-cell lung cancer	2C25.Y	Phase 3	[3]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[4]
AMG 757	DMLYP2N	Neuroendocrine cancer	2B72.1	Phase 1	[5]
AMG 119	DMKF1O2	Small-cell lung cancer	2C25.Y	Phase 1	[5]
RG6524	DMT22UV	Aggressive cancer	2A00-2F9Z	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04471727) Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
5	Clinical pipeline report, company report or official report of Amgen.
6	Clinical pipeline report, company report or official report of Roche